

RACP Foundation Research Awards

PROGRESS REPORT

Project / Program Title		Population-level vaccine safety monitoring: risk assessment and policy implications
Name		Dr Anastasia Phillips
Award Received		2018 RACP NHMRC JJ Billings Scholarship
Report Date		4 February 2019
Chief Investigator / Supervisor		Professor Kristine Macartney
Administering Institution		The University of Sydney
Funding Period	Start Date:	1 April 2018
	Finish Date:	31 March 2021

PROJECT SUMMARY

Immunisation has been hugely successful in reducing vaccine-preventable diseases and deaths. As these diseases become less common, there is increasing focus on any potential risks of immunisation. While vaccine safety is tested in clinical trials before vaccines become available, ongoing safety monitoring is important. Many different methods may be used in Australia and internationally to monitor and investigate vaccine safety. These methods have some limitations and findings can be taken out of context, leading to errors in assumptions about the safety of vaccines. This PhD is examining the usefulness of both existing and novel safety data and methodology to monitor vaccine safety. The best approach to interpreting this information and balancing risks and benefits will be examined.

PROJECT AIMS / OBJECTIVES

1. To evaluate the usefulness and quality of Australian data sources for vaccine safety monitoring through the manipulation of existing and novel data sources, focusing on specific vaccines.

This objective is being achieved through review of the usefulness and limitations of traditional and novel data sources including analysis of Therapeutic Goods Administration (TGA) and general practice (GP) data.

2. To assess the impact of safety data on immunisation program policy and develop a framework for assessment by policy-makers of the risk-benefit profile of Australian immunisation programs.

 145 Macquarie Street, Sydney NSW 2000, Australia
 Tel: +61 2 9256 5444
 Fax: +61 2 9252 3310

 Email: racp@racp.edu.au
 Web: www.racp.edu.au
 ACN 000 039 047
 ABN 90 270 343 237

This objective will be achieved through a qualitative research methodology in the later stages of the PhD program.

SIGNIFICANCE AND OUTCOMES

The HPV review article and conference presentation were well received internationally and identified a large volume of robust scientific evidence that supports the safety of the HPV vaccine. The review brought together published evidence supporting the position of expert groups in finding no evidence of any safety issue that should impact the use of this vaccine in immunisation programmes worldwide. It highlighted the importance of communication given that assumptions based on insufficient evidence may lead to unjustified loss of confidence in vaccine safety.

As Australia was the first country to implement a nationally funded HPV program, the next piece of research analysing 11 years of post-marketing Please also list any data on HPV vaccine from the TGA will provide robust and valuable safety proposed future information.

PUBLICATIONS / PRESENTATIONS

Macartney K, Phillips A, Patel C, Pillsbury A, Brotherton J. Authors' reply: Safety of human papillomavirus vaccines. Drug Saf. 2018; 41(5):541-543. Available from https://doi.org/10.1007/s40264-018-0655-1

Phillips A, Beard F, Macartney K, Chan J, Gilmour R, Saravanos G, Mcintyre P. Vaccinepreventable child deaths in New South Wales from 2005 to 2014: How much is preventable? J Paediatr Child Health. 2018; 54(4): 356-364. Available from http://onlinelibrary.wiley.com/doi/10.1111 /jpc.13835/full

Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of Human Papillomavirus Vaccines: An Updated Review. Drug Saf. 2017; 41 (4): 329-346. Available from https://doi.org/10. 1007 /s40264-017-0625-z

Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of Human Papillomavirus Vaccines: An Updated Review. In: PHAA 16th National Immunisation Conference, 2018: Adelaide, Australia.

Hiam R, Gowland A, Behm C, Phillips A. Macartney K. Live vaccine administration to immunocompromised patients: use of active surveillance data to enhance vaccine signal investigation. In: Asian Conference on Pharmacoepidemiology (ACPE); 2017: Brisbane, Australia.

Phillips A, Beard F, Macartney K, Chan J, Gilmour R, Saravanos G, Mcintyre P. Child deaths from vaccine preventable infectious diseases, New South Wales, 2005 to 2014. In: PHAA Communicable Disease Conference; 2017: Melbourne, Australia.